LMNL 6511
Alternative Names: LMNL-6511Latest Information Update: 22 Jun 2023
At a glance
- Originator Liminal BioSciences
- Class Anti-inflammatories; Antifibrotics; Small molecules
- Mechanism of Action GPR84 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Inflammation; Renal fibrosis
Most Recent Events
- 02 Jun 2023 Liminal BioSciences anticipates for CTA filling approval to conduct a phase I first-in-human clinical trial in healthy subjects in China in the second half of 2023
- 02 Jun 2023 Pharmacodynamics data from a preclinical trial in Inflammation released by Liminal Biosciences
- 12 Jan 2023 LMNL 6511 is available for licensing as of 06 Jan 2023. https://liminalbiosciences.com/